Drug-resistant ringworm detected in US for first time, CDC says

For the primary time, two instances of extremely contagious drug-resistant ringworm infections have been detected in america, based on the Facilities for Illness Management and Prevention. 

The CDC says the infections had been present in two sufferers in New York Metropolis who didn’t enhance with therapies. 

CDC headquarters

A common view of the Facilities for Illness Management and Prevention (CDC) headquarters in Atlanta, Ga. (REUTERS/Tami Chappell, File)

The primary affected person was a 28-year-old lady who developed a “widespread pruritic eruption” in the summertime of 2021. The lady, who was pregnant on the time of prognosis, had no identified exposures to an individual with an identical rash and no journey historical past. 

A second particular person, a 47-year-old lady, had developed a widespread pruritic eruption in the summertime of 2022 whereas in Bangladesh. After returning to the U.S., she was prescribed a number of therapies with out enchancment. 

Each girls required weeks of remedy to rid themselves of the an infection. 


A New York Metropolis dermatologist notified public well being officers of each sufferers who had extreme tinea that didn’t enhance with oral terbinafine therapy, elevating concern for potential “Trichophyton indotineae” an infection. Over the previous decade, there was an epidemic of extreme, antifungal-resistant pores and skin an infection known as tinea – generally referred to as “ringworm” – in South Asia due to the speedy rise of T. indotineae. 

T. indotineae infections have been reported all through Asia, Europe and Canada, however not the U.S. 

CLICK HERE TO GET THE Alokito Mymensingh 24 Alokito Mymensingh 24P

The CDC says the primary affected person’s lack of journey would possibly counsel potential native U.S. transmission of T. indotineae. 

It urged well being care suppliers that suspect T. indotineae an infection to contact its corresponding state or native public well being division for help with testing. 

Peter Johnson